-+ 0.00%
-+ 0.00%
-+ 0.00%

Voyager plans IND filing for Alzheimer’s gene therapy VY1706 in Q2 2026

PUBT·04/27/2026 20:59:17
Listen to the news
Voyager plans IND filing for Alzheimer’s gene therapy VY1706 in Q2 2026
  • Voyager Therapeutics flagged new preclinical safety and pharmacology results for Alzheimer’s gene therapy candidate VY1706 ahead of a late-breaking presentation at ASGCT 2026 on May 13.
  • Data from a 3-month GLP toxicology study in non-human primates supported an encouraging safety profile for intravenous delivery.
  • Voyager kept timeline for an IND submission in Q2 2026, targeting first-in-human dosing in 2H 2026.
  • Additional ASGCT presentations will outline earlier-stage capsid work aimed at expanding beyond CNS delivery, reducing immune recognition, improving manufacturability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.